ReviewJournal of ginseng research2025
Pyroptosis: A pharmacological target of ginseng and its phytochemical components for human inflammatory diseases.
Review in Journal of ginseng research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Ginsenosides Rh2 and Rg3 in first-line combination therapy: Prospects for rapid clinical translation in drug-resistant triple-negative breast cancer.Journal of ginseng research · 2026Review
- Korean red ginseng saponins ameliorate metabolic dysfunction-associated steatohepatitis in mice by inhibiting caspase-11 and NLRP3 inflammasomes.Journal of ginseng research · 2026Article
- A review of pharmacological properties and pharmacokinetic of 20(S)-protopanaxadiol.Journal of ginseng research · 2026Review
- 20(S)-protopanaxadiol enhances temozolomide responsiveness in MGMT-expressing glioblastoma: Wnt/β-catenin attenuation and MGMT downregulation.Frontiers in medicine · 2026Article
- The Role of Traditional Chinese Medicine in Acute Lung Injury: Targeting Programmed Cell Death.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pyroptosis is an intensely inflammatory form of lytic programmed cell death, typically triggered by pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) and is likely to form part of the inflammatory responses. It is driven by inflammasome activation during the triggering phase of inflammatory responses rather than the priming phase. Due to its role in inflammation, pyroptosis has been explored as a potential therapeutic target for suppressing inflammatory responses and treating inflammatory diseases. With growing evidence that ginseng and its primary bioactive compounds, ginsenosides, exert anti-inflammatory effects by inhibiting inflammasomes, their potential role in targeting pyroptosis for treating inflammatory diseases is particularly significant. Recent studies have highlighted the inhibitory effects of ginseng and ginsenosides on pyroptosis, along with the underlying mechanisms in inflammatory conditions. This review provides a comprehensive analysis of research investigating the pyroptosis-targeted anti-inflammatory properties of ginseng and ginsenosides, emphasizing their potential as herbal therapeutics for the prevention and treatment of pyroptosis-driven inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.